MetaVia Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
MetaVia announced interim Phase 1 Part 3B results for DA-1726 (a GLP-1/glucagon dual agonist) showing 68% placebo-adjusted liver-fat reduction (MRI-PDFF), 13.5% placebo-adjusted weight loss, and –0.24 pp placebo-adjusted HbA1c reduction at Day 109 (16 weeks) in 15 obese adults vs. 4 placebo. All 5 participants with baseline liver steatosis normalized to MRI-PDFF <5%; 83% achieved ≥30% liver-fat reduction. No new GI adverse events after Week 9; zero study discontinuations due to GI events. The company plans a 48-week, non-biopsy Phase 2 study in up to 150 patients with MetALD/ALD, targeted to start H2 2027; full Part 3A/3B data expected Q1 2027.
Why this rating
Strong preclinical liver efficacy in a $3M company; MetALD (10.7M US patients, zero approved therapies) is a major white space. Early-stage, small sample but statistically significant endpoints. Catalysts well-defined through 2027. Meaningful relative to company size; positive clinical data de-risks the program and opens a large untapped indication.
Tradability signal
NO TRADE
No trade: positive news with only -3.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.01% over 4 hrs, n=365). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.29 ▲ 6.61% | at our read · unknown $1.21 | +10 min · unknown $1.21 ▼ 0.41% | +30 min · unknown $1.15 ▼ 5.37% | +1 hr · unknown $1.16 ▼ 4.55% | +4 hrs · unknown $1.05 ▼ 13.22% |
The stock had already moved -6.20% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.